Zhu et al. [21] confirmed through mouse model and in vitro experiments that SIRT1 can inhibit mTOR phosphorylation, inhibit inflammation and fibrosis, and achieve the effect of improving scleroderma, suggesting that SIRT1 has a certain therapeutic effect on systemic sclerosis. Here, SIRT1 is linked to systemic sclerosis.